Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Eli Lilly & Co. is investing another $50 million in the Lilly MDR-TB Partnership, a consortium of 14 public and private organizations aligned to battle multi-drug-resistant tuberculosis. The cash influx brings Lilly's total investment in the project during the past four years to $120 million. Lilly also has provided several generic drugmakers with manufacturing and formulation technology needed to produce capreomycin and cycloserine, two Lilly antibiotics used to treat MDR-TB. In conjunction with Lilly's donation, the firms participating in the alliance will work to ramp up supplies of the antibiotics.
This article has been sent to the following recipient: